Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4380-4390

  Ermoli, Antonella ^a   Bargiotti, Alberto ^a   Brasca, Maria Gabriella ^a   Ciavolella, Antonella ^a   Colombo, Nicoletta ^a   Fachin, Gabriele ^a   Isacchi, Antonella ^a   Menichincheri, Maria ^a   Molinari, Antonio ^a   Montagnoli, Alessia ^a   Pillan, Antonio ^a   Rainoldi, Sonia ^a   Sirtori, Federico Riccardi ^a   Sola, Francesco ^a   Thieffine, Sandrine ^a   Tibolla, Marcellino ^a   Valsasina, Barbara ^a   Volpi, Daniele ^a   Santocanale, Corrado ^b   Vanotti, Ermes ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1H PYRROLO[2,3 B]PYRIDINE DERIVATIVE; 2 (BENZYLAMINO) 5 (1H PYRROLO[2,3 B]PYRIDIN 3 YLMETHYLENE) 1,3 THIAZOL 4(5H) ONE; 2 PHENYL 5 (1H PYRROLO[2,3 B]PYRIDIN 3 YLMETHYLENE) 3,5 DIHYDRO 4H IMIDAZOL 4 ONE DERIVATIVE; 7 AZAINDOLE DERIVATIVE; ANTINEOPLASTIC AGENT; CDC 7 KINASE; CDC 7 KINASE INHIBITOR; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CHEMICAL BOND; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR WEIGHT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

CELL CYCLE PROTEINS; CELL LINE; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650754045     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900248g     Document Type: Article

References (36)

1. Bell, S. P.; Dutta, A. DNA replication in eukaryotic cells. Annu. Rev. Biochem. 2002, 71, 333-374.
2. Kumagai, H.; Sato, N.; Yamada, M.; Mahony, D.; Seghezzi, W.; Lees, E.; Arai, K.; Masai, H. A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells. Mol. Cell. Biol. 1999, 19, 5083-5095.
3. Montagnoli, A.; Bosotti, R.; Villa, F.; Rialland, M.; Brotherton, D.; Mercurio, C.; Berthelsen, J.; Santocanale, C. Drf1, a novel regulatory subunit for human Cdc7 kinase. EMBO J. 2002, 21 (12), 3171-3181.
4. Hess, G. F.; Drong, R. F.; Weiland, K. L.; Slightom, J. L.; Sclafani, R. A.; Hollingsworth, R. E. A human homologue of the yeast CDC7 gene is overexpressed in some tumors and transformed cell lines. Gene 1998, 211 (1), 133-140.
5. Bonte, D.; Lindvall, C.; Liu, H.; Dykema, K.; Furge, K.; Weinreich, M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia (Ann Arbor, MI, U.S.) 2008, 10 (9), 920-931.
6. Jiang, W.; McDonald, D.; Hope, T. J.; Hunter, T. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J. 1999, 18, 5703-5713.
7. Montagnoli, A.; Tenca, P.; Sola, F.; Carpani, D.; Brotherton, D.; Albanese, C.; Santocanale, C. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res. 2004, 64, 7110-7116.
8. Montagnoli, A.; Valsasina, B.; Brotherton, D.; Troiani, S.; Rainoldi, S.; Tenca, P.; Molinari, A.; Santocanale, C. Identification of Mcm2 Phosphorylation Sites by S-phase-regulating Kinases. J. Biol. Chem. 2006, 281, 10281-10290.
9. Charych, D.; Coyne, M.; Yabannavar, A.; Narberes, J.; Chow, S.; Wallroth, M.; Shafer, C. M.; Walter, A. Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells. J. Cell. Biochem. 2008, 104 (3), 1075-1086.
10. Vanotti, E.; Amici, R.; Bargiotti, A.; Berthelsen, J.; Bosotti, R.; Ciavolella, A.; Cirla, A.; Cristiani, C.; D'Alessio, R.; Forte, B.; Martina, K.; Menichincheri, M.; Molinari, A.; Montagnoli, A.; Orsini, P.; Pillan, A.; Roletto, F.; Scolaro, A.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; Santocanale, C. Cdc7 Kinase I nhibitors: Pyrrolopyridinones as Antitumor Agents. 1. Synthesis and Structure-Activity Relationships. J. Med. Chem. 2008, 51, 487-501.
11. (a) Montagnoli, A.; Valsasina, B.; Croci, V.; Menichincheri, M.; Rainoldi, S.; Marchesi, V.; Tibolla, M.; Tenca, P.; Brotherton, D.; Albanese, C.; Patton, V.; Alzani, R.; Ciavolella, A.; Sola, F.; Molinari, A.; Volpi, D.; Avanzi, N.; Fiorentini, F.; Cattoni, M.; Healy, S.; Ballinari, D.; Pesenti, E.; Isacchi, A.; Moll, J.; Bensimon, A.; Vanotti, E.; Santocanale, C. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat. Chem. Biol. 2008, 4 (6), 357-365.
12. (b) Jackson, P. K. Stopping replication, at the beginning. Nat. Chem. Biol. 2008, 4 (6), 331-332.
13. Menichincheri, M.; Bargiotti, A.; Berthelsen, J.; Bertrand, J. A.; Bossi, R.; Ciavolella, A.; Cirla, A.; Cristiani, C.; Croci, V.; D0Alessio, R.; Fasolini, M.; Fiorentini, F.; Forte, B.; Isacchi, A.; Martina, K.; Molinari, A.; Montagnoli, A.; Orsini, P.; Orzi, F.; Pesenti, E.; Pezzetta, D.; Pillan, A.; Poggesi, I.; Roletto, F.; Scolaro, A.; Tato, M.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; Santocanale, C.; Vanotti, E. First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery. J. Med. Chem. 2009, 52, 293-307.
14. For a review: (a) Sawa, M.; Masai, H. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des. Dev. Ther. 2008, 2, 255-264.
15. (b) Ito, S.; Taniyama, C.; Arai, N.; Masai, H. Cdc7 as a potential new target for cancer therapy. Drug News Perspect. 2008, 21 (9), 481-488.
16. Robertson, S. Identification of XL413, a Selective Cdc7 Kinase Inhibitor Which Induces Cell Cycle Arrest and Exhibits Potent Antitumor Activity. In AARC-NCI-EORTC International Conference, Geneva, Switzerland, Oct. 21-24, 2008.
17. Zhao, C.; Tovar, C.; Yin, X.; Xu, Q.; Todorov, I. T.; Vassilev, L. T.; Chen, L. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 319-323.
18. Shafer, C. M.; Lindvall, M.; Bellamacina, C.; Gesner, T. G.; Yabannavar, A.; Jia, W.; Lin, S.; Walter, A. 4-(1H-Indazol-5-yl)-6-phenylpyrimidin- 2(1H)-one analogs as potent CDC7 inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4482-4485.
19. Vanotti, E.; Angelucci, F.; Bargiotti, A.; Brasca, M. G.; Ermoli, A.; Menichincheri, M. Pyrrolopyridines as kinase inhibitors. International Patent Appl. WO2007/054508, 2007.
20. Pevarello, P.; Brasca, M. G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding. J. Med. Chem. 2004, 47, 3367-3380.
21. ter Haar, E.; Coll, J. T.; Austen, D. A.; Hsiao, H. M.; Swenson, L.; Jain, J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 2001, 8, 593-596.
22. Vulpetti, A.; Crivori, P.; Cameron, A.; Bertrand, J.; Brasca, M. G.; D'Alessio, R.; Pevarello, P. J. Structure-Based Approaches to Improve Selectivity: CDK2-GSK3β Binding Site Analysis. J. Chem. Inf. Model. 2005, 45, 1282-1290.
23. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24, 1770-1783.
24. Palancade, B.; Bensaude, O. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur. J. Biochem. 2003, 270, 3859-3870.
25. Cai, D.; Vaughan, M. L., Jr.; Zhang, X.; Shapiro, I. G. Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer Cells. Cancer Res. 2006, 66 (18), 9270-9280.
26. Cativiela, C.; Diaz de Villegas, M. D.; Garcia, J. I.; Mayoral, J. A.; Melendez, E. Stereoselective synthesis of (Z)-2-(acylamino)-3-hetaryl-2- propenoic acids. An. Quim., Ser. C: Quim. Org. Bioquim. 1985, 81, 56-61.
27. Galat, A. The reaction of phenylpyruvic acid and related compounds with ammonia. J. Am. Chem. Soc. 1950, 72, 4436-4439.
28. Kiec-Kononowicz, K.; Szymanska, E.; Motyl, M.; Holzer, W.; Bialecka, A.; Kasprowicz, A. Synthesis, spectral, and antimicrobial properties of 5-chloroarylidene aromatic derivatives of imidazolin-4-one. Pharmazie 1998, 53, 680-684.
29. Wang, S.; Fischer, P. M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 2008, 29 (6), 302-313.
30. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
31. Avdeef, A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol. 2005, 1, 325-342.
32. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes. J. Med. Chem. 1998, 41, 1007-1010.
33. Kerns, E. H.; Di, L.; Petusky, S.; Farris, M.; Ley, R.; Jupp, P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 2004, 93 (6), 1440-1453.
34. Colombo, M.; Sirtori, F. R.; Rizzo, V. A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 2004, 18, 511-517.
35. Blechta, V.; del Rio-Portilla, F.; Freeman, R. Long-range carbon-proton couplings in strychnine. Magn. Reson. Chem. 1994, 32, 134-137.
36. Breitmaier, E.; Voelter, W. Carbon-13 NMR Spectroscopy: High-Resolution Methods and Applications in Organic Chemistry and Biochemistry, 3rd ed.; VCH Publishers: New York, 1987; pp 143-144.